Gerard Platenburg

Gerard is a co-founder and has served as the Chief Scientific Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive background in RNA modulation and orphan drug discovery and development and is currently in charge of the Innovation unit. Gerard has more than twenty-five years of senior managerial experience in growing biotech companies. Prior to joining the company, Gerard worked at Isa Pharmaceuticals B.V. as its Chief Executive Officer. Gerard co-founded Prosensa Holding N.V., growing it to become a well-known clinical-stage RNA modulation company, and held various positions including Chief Executive Officer and Chief Development Officer. Gerard also worked at Pharming B.V. He is a passionate and driven pioneer of early-stage technologies. Gerard has a master’s degree in chemistry and molecular biology from Leiden University in 1987 and pursued Ph.D. work at Leiden University. Gerard is currently a board member at Yarrow Biotechnology and a scientific advisory board member at Hybridize Therapeutics.